已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Outcomes of Recombinant Zoster Vaccination in Herpes Zoster Ophthalmicus: A Secondary Analysis of the Zoster Eye Disease Study

医学 接种疫苗 安慰剂 儿科 危险系数 置信区间 疾病 临床试验 人口 比例危险模型 不利影响 免疫 免疫学 外科 随机对照试验 安慰剂对照研究 内科学 眼病 眼带状疱疹
作者
Dena Ballouz,Jiyu Kim,Andrea B. Troxel,Elisabeth J. Cohen,Bennie H. Jeng
出处
期刊:Cornea [Lippincott Williams & Wilkins]
标识
DOI:10.1097/ico.0000000000004253
摘要

PURPOSE: Although the recombinant zoster vaccine (RZV) has demonstrated high efficacy in prevention of herpes zoster, there are concerns about its safety in patients with herpes zoster ophthalmicus with no clear evidence regarding the benefit of combining RZV with suppressive antiviral therapy. This secondary analysis of the Zoster Eye Disease Study outcomes by RZV vaccination status aims to assess potential benefit and risk of vaccination. METHODS: The Zoster Eye Disease Study was conducted at 95 sites from November 2017 to June 2024. RZV administration, both before and after enrollment, was recorded on electronic data entry forms. Five hundred twenty-seven participants were randomized to receive 12 months of double-masked daily valacyclovir 1000 mg or placebo and then followed for 18 months. In this analysis, we evaluated the impact on study outcomes within 3 months of RZV vaccination and at 12 and 18 months. RESULTS: Of the 527 participants, 122 (23.1%) received RZV, 37 (7.0%) pre-enrollment (15 on valacyclovir and 22 on placebo), and 85 (16.1%) postenrollment (41 on valacyclovir and 44 on placebo). Among participants who received RZV after enrollment, end points occurred within 3 months after the first shot in 5/85 (5.9%), including 0 (0/41, 0%) on valacyclovir and 5 (5/44, 11.4%) on placebo (P = 0.057), after the second shot in 2/50 (4.0%), including 2 (2/26, 7.7%) on valacyclovir and 0 on placebo (P = 0.491). Over the first 12 months, the time-dependent Cox regression analysis estimated a hazard ratio of 0.726 for end points comparing those with RZV vaccination with those without [95% confidence interval (CI) 0.39-1.34, P = 0.303]. Over 18 months, the HR comparing valacyclovir without RZV with placebo was 0.75 (95% CI 0.56-0.99, P = 0.046), and comparing valacyclovir with RZV with placebo was 0.51 (95% CI 0.27-0.98, P = 0.042). CONCLUSIONS: Participants who received suppressive valacyclovir treatment compared with placebo had a significantly lower likelihood of new or worsening ocular adverse events at 18 months; the effect of valacyclovir was similar regardless of administration of RZV.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
无限的含羞草完成签到,获得积分10
刚刚
1秒前
清风携来春夏完成签到,获得积分10
2秒前
Ava的应助被谦让的语儿采纳,获得10
2秒前
OK的应助被林夕采纳,获得80
2秒前
砰砰里完成签到,获得积分10
3秒前
阿狸完成签到 ,获得积分10
4秒前
哈哈哈哈哈哈完成签到 ,获得积分10
4秒前
mm完成签到,获得积分10
4秒前
田様的应助被lmd采纳,获得10
6秒前
我爱科研完成签到 ,获得积分10
7秒前
7秒前
伶俐初蓝完成签到 ,获得积分10
8秒前
9秒前
科研通AI6.3的应助被Parker采纳,获得10
10秒前
molihuakai的应助被杨希采纳,获得10
11秒前
12秒前
kskfjs完成签到,获得积分10
12秒前
12秒前
李煜东完成签到,获得积分10
13秒前
CodeCraft的应助被江就采纳,获得30
13秒前
KON发布了新的文献求助10
14秒前
土豆发布了新的文献求助10
14秒前
14秒前
CAOHOU的应助被树123采纳,获得10
15秒前
Yoghurt完成签到,获得积分10
15秒前
丙午完成签到,获得积分10
15秒前
木华完成签到,获得积分10
16秒前
zzzzzzzz完成签到,获得积分10
18秒前
18秒前
18秒前
yangqisen完成签到 ,获得积分10
19秒前
大模型的应助被畅销款采纳,获得10
20秒前
Parker发布了新的文献求助10
21秒前
21秒前
22秒前
林夕发布了新的文献求助10
22秒前
juntang发布了新的文献求助10
22秒前
wwwf完成签到 ,获得积分10
22秒前
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
Grapes 1000
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179104
求助须知:如何正确求助?哪些是违规求助? 9569680
关于积分的说明 21806134
捐赠科研通 7774263
什么是DOI,文献DOI怎么找? 3433003
关于科研通互助平台的介绍 2556897
邀请新用户注册赠送积分活动 2478643